Understand the source comparison
PE-22-28 Dosage TREK-1 Channel Research Comparison
Neuroprotection (stroke) 10–15mg/kg IV bolus 4–6μM Single dose 42% infarct reduction at 12mg/kg within 60min of occlusion Narrow therapeutic window. Dose-timing critical Cardiac arrhythmia 15–20mg/kg IV infusion 6–8μM sustained 4–6 hours 67% reduction in ventr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Neuroprotection (stroke)
- 10–15mg/kg
- IV bolus
- 4–6μM
- Single dose
- 42% infarct reduction at 12mg/kg within 60min of occlusion
- Narrow therapeutic window. Dose-timing critical
- Cardiac arrhythmia
- 15–20mg/kg
- IV infusion
- 6–8μM sustained
- 4–6 hours
- 67% reduction in ventricular fibrillation at 18mg/kg continuous infusion
- Sustained levels required. Bolus dosing ineffective
- Mechanical pain
- 5–8mg/kg
- Subcutaneous
- 2–3μM
- 35% increased withdrawal threshold at 6mg/kg, ceiling effect above 10mg/kg
- Lower dose sufficient. Higher doses add no benefit
- Traumatic brain injury
- 12–15mg/kg
- 5–7μM
- Single dose within 2hr
- Reduced secondary injury cascade when dosed <2hr post-trauma
- Time-to-dose more critical than exact dose within range